PFG Investments LLC Acquires Shares of 985 BeOne Medicines Ltd. - Sponsored ADR $ONC

Key Points

• PFG Investments LLC acquired 985 shares of BeOne Medicines Ltd., valued at approximately $238,000, in the second quarter of the year.
• BeOne Medicines reported a quarterly earnings EPS of $0.84, surpassing the consensus estimate of $0.48 with revenues of $1.32 billion.
• Analysts have generally upgraded the stock, with target prices ranging from $330.00 to $385.00 and an average rating of "Moderate Buy".

PFG Investments LLC acquired a new stake in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 985 shares of the company's stock, valued at approximately $238,000.

Several other institutional investors have also bought and sold shares of the business. Farther Finance Advisors LLC bought a new position in BeOne Medicines during the second quarter valued at $39,000. Signaturefd LLC purchased a new stake in shares of BeOne Medicines in the second quarter valued at $49,000. Parallel Advisors LLC purchased a new stake in shares of BeOne Medicines in the second quarter valued at $59,000. Avanza Fonder AB purchased a new stake in shares of BeOne Medicines in the second quarter valued at $199,000. Finally, Aaron Wealth Advisors LLC purchased a new stake in shares of BeOne Medicines in the second quarter valued at $200,000. Institutional investors own 48.55% of the company's stock.

BeOne Medicines Trading Down 0.4%

ONC stock opened at $343.87 on Monday. The company has a market capitalization of $37.69 billion, a PE ratio of -198.77 and a beta of 0.31. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $355.30. The firm's 50-day moving average is $318.57 and its 200 day moving average is $273.89. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.48 by $0.36. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. On average, research analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ONC shares. Morgan Stanley increased their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday, June 27th. Royal Bank Of Canada increased their target price on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Wall Street Zen raised shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Friday. Finally, Barclays began coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They issued an "overweight" rating and a $385.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $336.30.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, insider Lai Wang sold 5,000 shares of the firm's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total transaction of $1,750,300.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO John Oyler sold 27,803 shares of the firm's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total transaction of $9,055,715.13. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 181,315 shares of company stock worth $54,839,498. 6.62% of the stock is currently owned by company insiders.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.